AJMC Insights Series features Kathleen Moore, MD, MS, a gynecologic oncologist and expert in ovarian cancer treatment. Dr Moore discusses various aspects of novel therapies for ovarian cancer ...

Last year was an outstanding period for deals focused on antibody–drug conjugates (ADCs), with Pfizer’s $43 billion acquisition of Seagen and AbbVie’s $10.1 billion buyout of ImmunoGen being among the ...

Antibody-drug conjugates (ADCs) are innovative treatments targeting specific cancer cell receptors, delivering cytotoxic agents directly to tumors, minimizing systemic exposure. ADCs have shown ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...

Researchers are exploring the effectiveness of combining antibody drug conjugates and immune checkpoint inhibitors in non-small cell lung cancer. Precision medicine has improved the prognosis for ...

Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer. Antibody-drug conjugates like Datroway ...

Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, announces the launch of its new IR820 and IR870 infrared dye antibody conjugates. For the ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage antibody visugromab can improve the anti-tumor activity ...

Antibody-drug conjugates (ADCs) represent an emerging class of therapeutics across solid tumor oncology and are already positioned as a cornerstone therapy for patients with urothelial carcinoma (UC).

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...